Key result
In vitro pretreatment of blood with valsartan and its metabolite V4HV significantly inhibited platelet aggregation (P=0.0001) and delayed closure time compared to baseline.
Why the study?
Does in vitro treatment with valsartan and its metabolite V4HV inhibit platelet activation in blood samples from subjects with cardiovascular risk factors?
Population
30 subjects with multiple risk factors for cardiovascular disease (blood samples used for in vitro assessment)
Comparison
In vitro pretreatment and incubation of blood… vs Autologous baseline activity (pre-treatment)
Design
Preclinical
Authors
Loading...
Should not change valsartan prescribing; hypothesis-generating for antiplatelet mechanisms in vascular disease.
Does in vitro treatment with valsartan and its metabolite V4HV inhibit platelet activation in blood samples from subjects with cardiovascular risk factors?
p-value: p=0.0001
Valsartan and its metabolite V4HV demonstrate significant in vitro antiplatelet effects, suggesting a potential additional mechanism for their cardiovascular benefits in vascular disease.
Serebruany et al. (2004) studied Multiple risk factors for cardiovascular disease (n=30). Valsartan and valeryl 4-hydroxy valsartan (V4HV) vs. Autologous baseline activity was evaluated on Platelet aggregation and surface receptor expression (p=0.0001). In vitro pretreatment of blood with valsartan and its metabolite V4HV significantly inhibited platelet aggregation (P=0.0001) and delayed closure time compared to baseline.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: